Popular Articles

Fertility Centers Of Illinois Crystal Lake Location Expands To Offer Holistic Treatments
Fertility Centers of Illinois (FCI), Crystal Lake location - part of one of the nation"s leading infertility treatment practices - has expanded its services to include an array of holistic treatments such as acupuncture, massage and nutrition counseling, in addition to free patient education seminars. FCI recognizes the growing benefits of integrating holistic therapies with medical treatment and with an increasing demand from patients, has extended its partnership with Pulling Down The Moon to create the first holistic center located within the fertility clinic.

Medical Industry Showers DOD With Free Travel
The health care industry funded "8,700 trips by Department of Defense personnel" from 1998 to 2007, at a cost of more than $10 million, the Center for Public Integrity reports. "In a joint project with Northwestern University"s Medill School of Journalism, the Center examined 22,000 travel disclosure forms filed by DOD personnel, and found that the medical industry was by far the biggest sponsor of free travel, accounting for about 40 percent of all trips. The sponsors included not only drug and device makers but also health foundations and trade groups often funded by those companies."
News of the day
ACOG Issues New Guidelines On Fetal Monitoring To Resolve Inconsistencies In Interpretation
The American College of Obstetrics and Gynecology recently published new guidelines on electronic fetal monitoring in an attempt to increase consistency in the way physicians interpret and act on the results, the New York Times reports. Electronic fetal monitoring, which was introduced in the 1970s, is used during labor for more than 85% of the four million infants born alive in the U.S. annually, the Times reports. According to the Times, use of fetal monitors became standard obstetrical practice before it was known if the benefits outweighed the risks. The new guidelines refine the meaning of various readings from fetal monitors and could help doctors make better decisions about whether to intervene during labor.According to experts, the widespread adoption of fetal monitoring has produced both negative and positive consequences, including significant increases in caesarean deliveries and the use of forceps during vaginal deliveries. Monitoring has not been found to reduce the risk of either cerebral palsy or fetal death resulting from inadequate oxygen to the fetal brain, as it was intended to do. Furthermore, lawyers commonly use monitoring results to support malpractice cases that might have little merit, which in turn has driven rising malpractice insurance costs and prompted some obstetricians to stop delivering infants.The new guidelines divide monitor readings into three categories to help doctors interpret readings more consistently. The old guidelines had two categories -- reassuring and non-reassuring -- and it was up to the obstetrician to determine whether a non-reassuring reading required intervention. Under the new guidelines, the first category applies when tracings of the fetal heart rate are normal and no specific action is required. The second category is for indeterminate tracings that require evaluation, continuous surveillance and re-evaluation. Obstetricians treating patients in this category should consider other clinical factors that could affect the fetus and whether the patient could be safely moved to category one, according to Catherine Spong of the Eunice Kennedy Shriver National Institute of Child Health and Human Development, which produced recommendations on which the guidelines are based. The final category is for abnormal tracings that require immediate evaluation and efforts to reverse the abnormal heart rate. The Times reports that more refinements to the guidelines are expected to be released in 2010 (Brody, New York Times, 7/7).
Nutrition

New Radiotherapy Technique Proven Safe, Less Toxic For Cancer Patients, University Of Pittsburgh Cancer Institute Study Finds

A new technique known as stereotactic body radiotherapy (SBRT) is safe for patients with recurrent head and neck cancers and may improve their quality of life, according to researchers from the University of Pittsburgh Cancer Institute (UPCI). Results of the phase I study were reported today in the International Journal of Radiation Oncology, Biology, Physics. Each year approximately 500,000 cases of squamous cell carcinoma of the head and neck are diagnosed worldwide. While treatment has improved with advances in surgery, radiation and chemotherapy, more than half of patients will die from recurrent disease. Treatment options for patients with recurrent disease are limited, and for many, surgery may not be an option, according to principal investigator Dwight E. Heron, M.D., director, Radiation Oncology Services, UPMC Cancer Centers. "Chemotherapy alone can provide this patient population some palliation and pain relief, but it doesn"t prolong survival," said Dr. Heron. "A few patients may be able to receive additional radiation treatments, but head and neck cancers, by their very nature, develop in very delicate areas of the body, which provide significant retreatment challenges." SBRT may offer these patients an alternative, noted Dr. Heron. "At the completion of our study, we found this treatment was tolerated very well. No maximum tolerated dose was reached, and no toxicities occurred that caused us to limit the dosing." SBRT is a relatively new technique using CyberKnife® technology, which delivers high doses of radiation with more precision than conventional techniques. The vast majority of patients complete treatment within 10 days. In the trial, 31 patients with recurrent, inoperable head and neck cancers were treated over a two-week period. PET-CT also was used to develop an individualized radiation treatment plan for each patient, allowing radiation oncologists to more accurately target the cancer while sparing healthy tissue. "Ultimately, SBRT offers patients a better quality of life. Instead of having to go through six or seven weeks of treatments that are often associated with significant toxicities, patients can receive treatment over a shorter course and still get the same outcomes compared to the current standard of care," said Dr. Heron. Study co-authors include Robert L. Ferris, M.D., Ph.D., Michalis Karamousiz, M.D., Regiane S. Andrade, M.D., Erin L. Deeb, B.S., Steven Burton, M.D., William E. Gooding, M.S., Barton F. Branstetter, M.D., James M. Mountz, M.D., Ph.D., Jonas T. Johnson, M.D., Anthanassios Argiris, M.D., Jennifer R. Grandis, M.D., Stephen Y. Lai, M.D., Ph.D., all of the University of Pittsburgh Cancer Institute. This study was funded by the University of Pittsburgh Cancer Institute. The University of Pittsburgh Cancer Institute


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):